3:02 PM
 | 
Feb 08, 2018
 |  BC Innovations  |  Translation in Brief

Proteomic pathfinding

How Biognosys is mapping cell-wide drug-protein interactions

Editor's Note: This article was updated on Feb 14, 2018 at 12:50 PM PST

Biognosys is using a method developed by ETHZ researchers for the unbiased detection of molecular targets based on protein-metabolite interactions to study inter- and intra-patient variances in the proteome.

The protein services CRO will also offer the method to clients to help identify the proteins targeted by small molecule hits from phenotypic screens and to elucidate the molecules’ modes of action.

Previous methods for characterizing interactions between proteins and small molecules, including metabolites and drug compounds, have generally relied on low-throughput in vitro activity assays for specific interaction pairs, which are time-intensive, cannot capture off-target effects, and often require the use of tags or labels that could alter the small molecule’s activity.

In a January study in Cell, the Swiss Federal Institute of Technology Zurich (ETHZ) team described a new method, dubbed limited proteolysis (LiP)-small molecule mapping (LiP-SMap), that detects...

Read the full 680 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >